Valuation : Sage Therapeutics, Inc.

Market Cap 544M 467M 437M 400M 754M 51.91B 756M 5.17B 2.02B 26.16B 2.04B 2B 86.59B P/E 2023
-2.39x
P/E 2024 -0.82x
Enterprise Value 50.98M 43.76M 40.97M 37.52M 70.67M 4.87B 70.87M 485M 190M 2.45B 191M 187M 8.12B EV / Sales 2023
6.4x
EV / Sales 2024 -3.89x
Free-Float
99.75%
Yield 2023 *
-
Yield 2024 -
3 years 4.62
Extreme 4.62
28.26
5 years 4.62
Extreme 4.62
59.99
10 years 4.62
Extreme 4.62
195.97
Manager TitleAgeSince
President 64 2025-07-30
General Counsel - 2020-07-31
Director TitleAgeSince
Director/Board Member 64 2025-07-30
Date Insider Type Main position Quantity % Market Cap.
7/31/25 Issuer sale

Director

21,500 0.0350%
7/31/25 Issuer sale

Chief Technology Officer

72,961 0.1187%
7/31/25 Tender

Director

43,499 0.0708%
Change 5-day change 1-year change 3-year change Capi.($)
-0.23%-.--%-.--%-56.45% 544M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.23% 65.4B
-0.65%+1.44%+9.20%-6.79% 28.28B
-0.49%+5.43%+54.81%+13.87% 26.57B
-1.64%-1.91%-8.80%+467.51% 27.16B
+0.37%+1.21%+36.55%-17.60% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%+0.19%+8.01%+520.34% 15.87B
-1.78%+2.55%+42.98%+148.24% 13.9B
Average +0.18%+1.04%+52.26%+168.63% 28.88B
Weighted average by Cap. +0.85%+0.72%+55.44%+155.34%

Financials

2023 2024
Net sales 86.46M 74.21M 69.48M 63.62M 120M 8.26B 120M 823M 322M 4.16B 325M 318M 13.77B 41.24M 35.4M 33.14M 30.35M 57.17M 3.94B 57.34M 392M 153M 1.99B 155M 152M 6.57B
Net income -541M -465M -435M -398M -751M -51.72B -753M -5.15B -2.01B -26.06B -2.03B -1.99B -86.26B -401M -344M -322M -295M -555M -38.27B -557M -3.81B -1.49B -19.29B -1.5B -1.47B -63.83B
Net Debt -748M -642M -601M -550M -1.04B -71.44B -1.04B -7.12B -2.78B -36.01B -2.81B -2.75B -119B -493M -423M -396M -362M -683M -47.05B -685M -4.69B -1.83B -23.71B -1.85B -1.81B -78.47B
Logo Sage Therapeutics, Inc.
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Employees
353
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SAGE Stock